Predictive Value of FMISO-PET, FDG-PET-CT, DWI-MRI and DCE-MRI Scans for Patients With Anal Cancer Receiving Radiotherapy +/- Chemotherapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01330186|
Recruitment Status : Unknown
Verified April 2011 by Copenhagen University Hospital at Herlev.
Recruitment status was: Recruiting
First Posted : April 6, 2011
Last Update Posted : April 12, 2011
|Condition or disease||Intervention/treatment|
|Anal Cancer||Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||18F-FMISO-PET, 18F-FDG-PET/CT, DWI-MRI and DCE-MRI Scans as Predictors of Response to Radiotherapy +/- Chemotherapy in Patients With Anal Cancer.|
|Study Start Date :||February 2011|
|Estimated Primary Completion Date :||February 2012|
|Estimated Study Completion Date :||May 2012|
Other: FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)
This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
- Tumor response [ Time Frame: 6-8 weeks post radiation ]
- Primary tumor 18-F-deoxyglucose (FDG) uptake before radiation and during week 3 of radiation.
- Primary tumor apparent diffusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation
- Primary tumor perfusion coefficient before radiation and during week 3 of radiation and 6-8 weeks post radiation
- Primary tumor 18-F-Fluoromisonidazol (FMISO) uptake before radiation
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01330186
|Contact: Eva Serup-Hansen, MDemail@example.com|
|Contact: Hanne Havsteen, MDfirstname.lastname@example.org|
|Department of Oncology Herlev Hospital||Recruiting|
|Herlev, Denmark, 2730|
|Contact: Eva Serup-Hansen, MD +4538689084 email@example.com|
|Contact: Hanne Havsteen, MD +4538682287 firstname.lastname@example.org|
|Principal Investigator: Eva Serup-Hansen, MD|